Biora Therapeutics Financial Statements
Biora Therapeutics Financial Overview
Biora Therapeutics's market cap is currently ―. The company's EPS TTM is $-2.32; its P/E ratio is -0.27; Biora Therapeutics is scheduled to report earnings on August 18, 2022, and the estimated EPS forecast is $-0.12. See an overview of income statement, balance sheet, and cash flow financials.
| Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 107.00K | $ 435.00K | $ 182.00K | $ 463.00K | $ 167.00K |
| Gross Profit | $ ― | $ 435.00K | $ 182.00K | $ 463.00K | $ 2.29M |
| EBIT | $ -19.91M | $ -32.55M | $ -33.42M | $ -37.90M | $ -31.46M |
| EBITDA | $ -19.59M | $ -32.18M | $ -33.32M | $ -37.38M | $ -31.02M |
| Net Income Common Stockholders | $ -13.81M | $ -92.87M | $ -43.74M | $ -78.53M | $ -32.26M |
| Balance Sheet | |||||
| Cash, Cash Equivalents and Short-Term Investments | $ 54.14M | $ 60.01M | $ 65.28M | $ 65.99M | $ 67.23M |
| Total Assets | $ 86.74M | $ 108.84M | $ 97.68M | $ 119.95M | $ 128.58M |
| Total Debt | $ 72.61M | $ 126.50M | $ 128.04M | $ 157.60M | $ 159.27M |
| Net Debt | $ 18.48M | $ 66.49M | $ 62.76M | $ 91.61M | $ 92.04M |
| Total Liabilities | $ 179.92M | $ 193.81M | $ 274.65M | $ 259.56M | $ 254.08M |
| Stockholders Equity | $ -93.19M | $ -84.98M | $ -176.97M | $ -139.61M | $ -125.51M |
| Cash Flow | |||||
| Free Cash Flow | $ -24.30M | $ -40.05M | $ -43.19M | $ -36.11M | $ -48.99M |
| Operating Cash Flow | $ -23.95M | $ -40.05M | $ -43.19M | $ -35.69M | $ -48.56M |
| Investing Cash Flow | $ -342.00K | $ 211.00K | $ -432.00K | $ -558.00K | $ -463.00K |
| Financing Cash Flow | $ 3.13M | $ 73.54M | $ 31.77M | $ 37.52M | $ 22.23M |